公开(公告)号：US08372439B2

公开(公告)日：2013-02-12

申请号：US13569140

申请日：2012-08-07

Applicant: John Daniel ,  Robert Tofe ,  Randall Spencer ,  John Russo

Inventor： John Daniel ,  Robert Tofe ,  Randall Spencer ,  John Russo

IPC: A61K35/50

CPC classification number: A61K35/28 ,  A61F2/02 ,  A61F2210/00 ,  A61F2230/00 ,  A61K9/7007 ,  A61K35/19 ,  A61K35/33 ,  A61K35/50 ,  A61L27/3604 ,  A61L27/3683 ,  A61L27/3834 ,  A61L27/56 ,  A61L2430/34 ,  A61L2430/40 ,  Y10T156/10 ,  Y10T156/1039

Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

Abstract translation: 这里描述的是来自胎盘的组织移植物。 移植物由至少一层羊膜组织组成，其中已经基本上去除了上皮层，以便将基底层暴露于宿主细胞。 通过去除上皮层，来自宿主的细胞可以更容易地与位于基底膜顶部和内部的细胞粘附生物活性因子相互作用。 本文还描述了用于制造和使用组织移植物的方法。 羊膜组织的层粘连蛋白结构与天然人体组织例如口腔粘膜组织几乎相同。 这包括高水平的层粘连蛋白-5，表现为结合牙龈上皮细胞的细胞粘附生物活性因子，其遍及基底膜的上部。

公开(公告)号：US08357403B2

公开(公告)日：2013-01-22

申请号：US12206508

申请日：2008-09-08

Applicant: John Daniel ,  Robert Tofe ,  Randall Spencer ,  John Russo

Inventor： John Daniel ,  Robert Tofe ,  Randall Spencer ,  John Russo

IPC: A61K35/50

CPC classification number: A61K35/28 ,  A61F2/02 ,  A61F2210/00 ,  A61F2230/00 ,  A61K9/7007 ,  A61K35/19 ,  A61K35/33 ,  A61K35/50 ,  A61L27/3604 ,  A61L27/3683 ,  A61L27/3834 ,  A61L27/56 ,  A61L2430/34 ,  A61L2430/40 ,  Y10T156/10 ,  Y10T156/1039

Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

公开(公告)号：US20130006385A1

公开(公告)日：2013-01-03

申请号：US13569116

申请日：2012-08-07

Applicant: John Daniel

Inventor： John Daniel

IPC: A61F2/02

CPC classification number: A61K35/50 ,  A61F2/02 ,  A61J1/00 ,  A61L27/3604 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3695 ,  A61L27/40 ,  A61L27/50 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/412 ,  A61L2300/60 ,  A61L2300/64 ,  A61L2430/40 ,  B65D25/205 ,  B65D81/18 ,  B65D85/70

Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.

公开(公告)号：US20120325641A1

公开(公告)日：2012-12-27

申请号：US13531506

申请日：2012-06-23

Applicant: John Daniel Elliott ,  David Allan Wedlake

Inventor： John Daniel Elliott ,  David Allan Wedlake

IPC: C10B57/04 ,  C10B55/10

CPC classification number: C10B57/04 ,  C10B53/02 ,  C10B55/02 ,  C10B55/10 ,  C10B57/045 ,  Y02E50/10 ,  Y02E50/14 ,  Y02E50/30 ,  Y02P20/145

Abstract: The invention relates to the production of a biofuel from a feedstock that includes a solid biomass material such as lemna. A hydrocarbon feedstock is fed into the coking process and reaction products generated from the thermal process are collected. The invention further relates to the production of a coke product having an isotropic structure.

Abstract translation: 本发明涉及从原料生产生物燃料，其包括固体生物质材料，例如莱姆纳（lemna）。 将烃原料进料到焦化过程中，并收集从热处理产生的反应产物。 本发明还涉及具有各向同性结构的焦炭产品的生产。

公开(公告)号：US20120294910A1

公开(公告)日：2012-11-22

申请号：US13569140

申请日：2012-08-07

Applicant: John Daniel ,  Robert Tofe ,  Randall Spencer ,  John Russo

Inventor： John Daniel ,  Robert Tofe ,  Randall Spencer ,  John Russo

IPC: A61K9/00 ,  A61K35/12

CPC classification number: A61K35/28 ,  A61F2/02 ,  A61F2210/00 ,  A61F2230/00 ,  A61K9/7007 ,  A61K35/19 ,  A61K35/33 ,  A61K35/50 ,  A61L27/3604 ,  A61L27/3683 ,  A61L27/3834 ,  A61L27/56 ,  A61L2430/34 ,  A61L2430/40 ,  Y10T156/10 ,  Y10T156/1039

Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

Abstract translation: 这里描述的是来自胎盘的组织移植物。 移植物由至少一层羊膜组织组成，其中已经基本上去除了上皮层，以便将基底层暴露于宿主细胞。 通过去除上皮层，来自宿主的细胞可以更容易地与位于基底膜顶部和内部的细胞粘附生物活性因子相互作用。 本文还描述了用于制造和使用组织移植物的方法。 羊膜组织的层粘连蛋白结构与天然人体组织例如口腔粘膜组织几乎相同。 这包括高水平的层粘连蛋白-5，表现为结合牙龈上皮细胞的细胞粘附生物活性因子，其遍及基底膜的上部。

公开(公告)号：US20120015918A1

公开(公告)日：2012-01-19

申请号：US13096895

申请日：2011-04-28

Applicant: John Daniel Dobak

Inventor： John Daniel Dobak

IPC: A61K31/137 ,  A61P3/00 ,  A61K31/27 ,  A61K31/573

CPC classification number: A61K31/138 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0021 ,  A61K9/5031 ,  A61K31/167 ,  A61K31/195 ,  A61K31/4535 ,  A61K31/567 ,  A61K31/573 ,  A61K31/58 ,  A61K47/10 ,  A61K47/14 ,  A61K47/34 ,  A61K47/36

Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.

Abstract translation: 用于治疗局部脂肪沉积物的组合物，制剂，方法和系统包括使目标脂肪沉积物与包含长效β-2肾上腺素能受体激动剂和减少靶组织对长效β-2肾上腺素能受体脱敏的化合物接触 激动剂，例如糖皮质激素和/或酮替芬。 组合物的实施方案例如通过注射和/或经皮施用。

公开(公告)号：US20120004564A1

公开(公告)日：2012-01-05

申请号：US13230084

申请日：2011-09-12

Applicant: John Daniel Dobak, III

Inventor： John Daniel Dobak, III

IPC: A61B5/0205 ,  A61B5/0402 ,  A61B5/0245

CPC classification number: A61B5/11 ,  A61B5/0031 ,  A61B5/021 ,  A61B5/0422 ,  A61B5/0452 ,  A61B5/0456 ,  A61B5/1102 ,  A61B5/6851 ,  A61B5/6852 ,  A61B5/6862 ,  A61B5/6869 ,  A61B5/6876 ,  A61B5/726 ,  A61B7/00 ,  A61B2562/028 ,  A61N1/3627

Abstract: Systems and methods according to the invention employ an acceleration sensor to characterize the synchrony or dyssynchrony of the left ventricle. Patterns of acceleration related to myocardial contraction can be used to assess synchrony or dyssynchrony. Time-frequency transforms and coherence are derived from the acceleration. Information and numerical indices determined from the acceleration time frequency transforms and coherence can be used to find the optimal pacing location for cardiac resynchronization therapy. Similarly, the information can be used to optimize timing intervals including V to V and A to V timing.

Abstract translation: 根据本发明的系统和方法采用加速度传感器来表征左心室的同步或不同步。 与心肌收缩相关的加速模式可用于评估同步或不同步。 时频变换和相干性来自加速度。 从加速时间频率确定的信息和数值指数变换和相干性可用于找到心脏再同步治疗的最佳起搏位置。 类似地，该信息可用于优化包括V至V和A至V定时的定时间隔。

公开(公告)号：US20110259430A1

公开(公告)日：2011-10-27

申请号：US13126232

申请日：2009-10-26

Applicant: John Daniel Friedemann

Inventor： John Daniel Friedemann

IPC: F15D1/00

CPC classification number: E21B43/121 ,  B01D19/0042 ,  B01D19/0063 ,  E21B43/34 ,  Y10T137/0318 ,  Y10T137/4259 ,  Y10T137/85978 ,  Y10T137/86324

Abstract: A separator arrangement in a multiphase production system. A closed separator container includes a top and a bottom, an inlet for production fluids at an inlet level and at least one outlet for at least partly separated liquid at a level lower than the inlet level. The container outlet is connectable to a liquid pump arranged downstream of the container. A gas accumulator is arranged for by-passing the pump. The gas accumulator includes an inlet end connectable to a top region of the container and an outlet end connectable to a discharge side of the pump for flow communication between the container and the discharge side of the pump. A region near the inlet end the gas accumulator is connected to a supply of injection liquid that is controllable via a valve to be injected to the discharge side of the pump via the gas accumulator. A method for gas by-pass of a liquid pump in a multiphase production system.

Abstract translation: 多相生产系统中的分离器装置。 封闭的分离器容器包括顶部和底部，用于在入口水平处的生产流体的入口和用于至少部分分离的液体在低于入口水平的水平的至少一个出口。 容器出口可连接到布置在容器下游的液体泵。 设置有用于旁路泵的气体蓄能器。 气体储存器包括可连接到容器的顶部区域的入口端和可连接到泵的排放侧的出口端，用于容器和排出侧之间的流动连通。 入口附近的区域的气体收集器连接到可经由阀门控制的注入液体供应源，以通过气体储存器喷射到泵的排放侧。 一种用于多相生产系统中的液体泵的气体旁路的方法。

公开(公告)号：USD642193S1

公开(公告)日：2011-07-26

申请号：US29364633

申请日：2010-06-25

Applicant: Patrick Shih ,  John Daniel Hayes Leonard ,  Wilhelmina P. Dietrich ,  Kristie E. Smith ,  Ojiakonobi Udezue

Designer： Patrick Shih ,  John Daniel Hayes Leonard ,  Wilhelmina P. Dietrich ,  Kristie E. Smith ,  Ojiakonobi Udezue

公开(公告)号：US20110130373A1

公开(公告)日：2011-06-02

申请号：US12788190

申请日：2010-05-26

Applicant: John Daniel Dobak ,  Kenneth Walter Locke

Inventor： John Daniel Dobak ,  Kenneth Walter Locke

IPC: A61K31/56 ,  A61K31/138 ,  A61K31/167 ,  A61K31/573 ,  A61K31/58 ,  A61P3/04 ,  A61P43/00

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K31/137 ,  A61K31/167 ,  A61K31/56 ,  A61K31/568 ,  A61K31/573 ,  A61K31/58 ,  A61K2300/00

Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.

Abstract translation: 本文提供了用于治疗局部脂肪沉积物和脂肪相关病症和适应症的药物制剂，方法和系统。 方法包括施用基本上由适于皮下给药的长效β-2肾上腺素能受体激动剂例如沙美特罗组成的药物制剂。 方法还包括施用适于皮下注射的药物制剂，其包含：（a）亲脂性长效选择性β-2肾上腺素能受体激动剂和/或糖皮质激素，或其盐，旋光异构体，外消旋体，溶剂化物或多晶型物; 和（b）至少一种皮下可接受的无活性成分。